Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.

about

Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.

Item

http://www.wikidata.org/entity/Q51842580

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Venetoclax: A novel B-cell lym ...... ther hematologic malignancies.

@en

Venetoclax: A novel B-cell lym ...... ther hematologic malignancies.

@nl

type

Item

label

Venetoclax: A novel B-cell lym ...... ther hematologic malignancies.

@en

Venetoclax: A novel B-cell lym ...... ther hematologic malignancies.

@nl

prefLabel

Venetoclax: A novel B-cell lym ...... ther hematologic malignancies.

@en

Venetoclax: A novel B-cell lym ...... ther hematologic malignancies.

@nl

P1476

Venetoclax: A novel B-cell lym ...... ther hematologic malignancies.

@en

P2093

Carrie L Griffiths

http://www.w3.org/2001/XMLSchema#string

Jacqueline L Olin

http://www.w3.org/2001/XMLSchema#string

Morgan B Smith

http://www.w3.org/2001/XMLSchema#string

P2860

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Genomic aberrations and survival in chronic lymphocytic leukemia

Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base.

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

P304

1078155217718383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155217718383

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28696175

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte